These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 2059756

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
    Koga Y, Nagatoshi Y, Kawano Y, Okamura J.
    Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
    [Abstract] [Full Text] [Related]

  • 23. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S.
    Blood Cells Mol Dis; 2008 Jul; 40(1):48-54. PubMed ID: 17827036
    [Abstract] [Full Text] [Related]

  • 24. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
    Schwinghammer TL, Bloom EJ.
    Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F, Copelan E, Crilley P, Bolwell B, Avalos B, Klein J, Territo M, Gajewski J.
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [Abstract] [Full Text] [Related]

  • 31. [Unrelated donor stem cell transplantation in children: low toxicity using a GvHD-prophylaxis regimen with CSA, MTX, metronidazole,iv-immunoglobulin and ATG].
    Graf Finckenstein F, Zabelina T, Dürken M, Dahlke J, Kröger N, Krüger W, Janka-Schaub G, Erttmann R, Zander AR, Kabisch H.
    Klin Padiatr; 2002 May; 214(4):206-11. PubMed ID: 12165903
    [Abstract] [Full Text] [Related]

  • 32. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
    Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Kabisch H, Jaburg N, Löliger C, Krüll A, Zander AR.
    Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
    [Abstract] [Full Text] [Related]

  • 33. [Prophylaxis with FK-506 for graft-versus-host disease after transplantation of bone marrow from unrelated donors].
    Hamazaki T, Yagi K, Inoue M, Sakata N, Okamura T, Yasui M, Sasabe M, Kishimoto T, Inoue A, Kawa K.
    Rinsho Ketsueki; 2000 May; 41(5):430-6. PubMed ID: 10879106
    [Abstract] [Full Text] [Related]

  • 34. Bone marrow transplantation from matched related donors for patients with Fanconi anemia using low-dose busulfan and cyclophosphamide as conditioning.
    Torjemane L, Ladeb S, Ben Othman T, Abdelkefi A, Lakhal A, Ben Abdeladhim A.
    Pediatr Blood Cancer; 2006 Apr; 46(4):496-500. PubMed ID: 16333862
    [Abstract] [Full Text] [Related]

  • 35. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M, Perrin MC, Belhabri A, Molina L, Nicolini F, Tigaud JD, Sotto JJ, Guyotat D, Fière D, Archimbaud E.
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [Abstract] [Full Text] [Related]

  • 36. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial.
    Chao NJ, Snyder DS, Jain M, Wong RM, Niland JC, Negrin RS, Long GD, Hu WW, Stockerl-Goldstein KE, Johnston LJ, Amylon MD, Tierney DK, O'Donnell MR, Nademanee AP, Parker P, Stein A, Molina A, Fung H, Kashyap A, Kohler S, Spielberger R, Krishnan A, Rodriguez R, Forman SJ, Bluzme KG.
    Biol Blood Marrow Transplant; 2000 Jan; 6(3):254-61. PubMed ID: 10871150
    [Abstract] [Full Text] [Related]

  • 37. Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia.
    Weaver CH, Clift RA, Deeg HJ, Storb R, Appelbaum FR, Bensinger W, Doney K, Hansen JA, Martin PO, Sanders J.
    Bone Marrow Transplant; 1994 Dec; 14(6):885-93. PubMed ID: 7711667
    [Abstract] [Full Text] [Related]

  • 38. Six weeks of continuous intravenous cyclosporine and short-course methotrexate as prophylaxis for acute graft-versus-host disease after allogeneic bone marrow transplantation.
    Beelen DW, Quabeck K, Kaiser B, Wiefelspütz J, Scheulen ME, Graeven U, Grosse-Wilde H, Sayer HG, Schaefer UW.
    Transplantation; 1990 Sep; 50(3):421-7. PubMed ID: 2402791
    [Abstract] [Full Text] [Related]

  • 39. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate.
    Nash RA, Pepe MS, Storb R, Longton G, Pettinger M, Anasetti C, Appelbaum FR, Bowden RA, Deeg HJ, Doney K.
    Blood; 1992 Oct 01; 80(7):1838-45. PubMed ID: 1391947
    [Abstract] [Full Text] [Related]

  • 40. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants?
    Storb R, Pepe M, Anasetti C, Appelbaum FR, Beatty P, Doney K, Martin P, Stewart P, Sullivan KM, Witherspoon R.
    Blood; 1990 Sep 01; 76(5):1037-45. PubMed ID: 2203481
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.